Premium
Pharmacokinetics and intramuscular bioavailability of amikacin in chickens following single and multiple dosing
Author(s) -
ELGAMMAL A. A.,
RAVISt W. R.,
KRISTA L. M.,
TOLBERT D. S.,
SAAD A.
Publication year - 1992
Publication title -
journal of veterinary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 60
eISSN - 1365-2885
pISSN - 0140-7783
DOI - 10.1111/j.1365-2885.1992.tb01000.x
Subject(s) - dosing , bioavailability , pharmacokinetics , amikacin , pharmacology , medicine , chemistry , antibiotics , biochemistry
The pharmacokinetics of amikacin were studied in healthy mature female chickens ( n = 6). Single doses of amikacin were injected as an i.v. bolus (10 mg/ kg) and im. (20 mg/kg) into the same birds with a 30‐day rest period between treatments. Amikacin was determined by the fluorescence polarization im‐munoassay method. The i.v. pharmacokinetics could be described by a two‐compartment model with a t 1/2α of 0.150 ± 0.064 h and a t 1/2β of 1.44 ± 0.34 h. The total body clearance was 0.109 ± 0.017 l/h/kg and the volume of distribution at steady‐state was 0.193 ± 0.060 Vkg. Following a single i.m. injection. the peak plasma concentration (C max ) was 50.79 ± 4.05 μg/ml and occurred at 0.50 ± 0.26 h. The i.m. extent of absorption was 91.2 ± 17.65%. Simultaneous modeling of i.v. antl i.m. results provided estiinates of an absorption half‐life of 0.480 ± 0.158 h. The i.m. pharmacokinetics after repeated administration were stittlied following the tenth close (20 mg/kg, every 8 h). The C ss max was 38.58 ± 6.96 pgi nil and occurred at 0.79 ± 0.37 11, and the biological half‐life of aniikncin was 1.86 5 0.47 11. The multiple closing yielded peak concentrations of 39 μg/ml and trough concentrations of 3.26 μg/ml. Based on these data, the recomnienclecl amikacin dosage in chickens is 20 mg/kg body weight every 8 h.